Ho Bae, MD
Gastroenterology · Los Angeles, CANPI 1053337998
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,010 of the $24,312 with a category attached, or 78.2%. Gilead accounts for 83.1% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $15,490 and has fallen 77.5% since, to $3,478 in 2025.
Across 67 payments — averaging $362.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$20K
- GSK$3K
- Amgen$358
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$125
- Ardelyx, Inc.$96
- Intercept Pharmaceuticals, Inc.$94
- plus $226 from 6 others
Across 70 payments — averaging $2685.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$161K
- Eiger Biopharmaceuticals, Inc.$27K
What the payments were for
- Consulting fees$3,20013%
- Speaking & faculty fees$19,01078%
- Travel & lodging$920%
- Food & beverage$1,9418%
- Education$690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 45 | $20,213 |
| GSK | 1 | $3,200 |
| Amgen | 3 | $358 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $125 |
| Ardelyx, Inc. | 3 | $96 |
| Intercept Pharmaceuticals, Inc. | 2 | $94 |
| Phathom Pharmaceuticals, Inc. | 4 | $70 |
| AbbVie(2 entities) | 3 | $57 |
| Bristol Myers Squibb | 2 | $42 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Boston Scientific | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,312 in reported general payments places this provider in the 85th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VemlidyTenofovir Alafenamide | 269 | $379,664 |
| XifaxanRifaximin | 52 | $169,981 |
| Tenofovir Disoproxil Fumarate | 268 | $35,087 |
| CreonLipase/Protease/Amylase | 29 | $34,969 |
| LinzessLinaclotide | 39 | $25,909 |
| BaracludeEntecavir | 18 | $22,933 |
| Entecavir | 138 | $20,242 |
| Ursodiol | 53 | $11,613 |
| Mesalamine | 30 | $8,019 |
| Azathioprine | 34 | $4,061 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 62 | $3,773 |
| Pantoprazole Sodium | 501 | $2,991 |
| Budesonide DrBudesonide | 14 | $2,575 |
| Budesonide EcBudesonide | 13 | $1,370 |
| Tacrolimus | 37 | $1,367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadVemlidy | $20,213 | $379,664269 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $125 | $169,98152 claims |
| AbbVieCreon, Linzess | $57 | $60,87868 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in Los Angeles
- Bennett RothLos Angeles$2.8M
- Sammy SaabLos Angeles$1.9M
- Sadeea AbbasiLos Angeles$556K
- Gil MelmedLos Angeles$467K
- Venkataraman MuthusamyLos Angeles$297K
- Caroline HwangLos Angeles$279K
- Adarsh ThakerLos Angeles$241K
- Andres YarurLos Angeles$218K
- Joseph PisegnaLos Angeles$210K
- Steven-Huy HanLos Angeles$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.